argenx SE
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
20 feb 2024 - 07:05
Statutory name
argenx SE
Title
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Related downloads
Date last update: 03 April 2026